Skip to content

The effects of propofol and sevoflurane on patients with Parkinson's undergoing DBS

The effects of propofol and sevoflurane on patients with Parkinson's undergoing DBS

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076008
Enrollment
Unknown
Registered
2023-09-21
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's

Interventions

Intravenous anesthesia group:Total intravenous anesthesia maintenance by propofol
nhalation anesthesia maintenance:nesthesia maintenance by sevoflurane

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Select patients aged 18-65 with primary Parkinson's disease; 2. It is effective for levodopa drugs and the experimental response rate of levodopa drugs is>30%; 3. No cognitive impairment, no serious depression, anxiety or other mental illness complications; 4. The head MRI examination is basically normal, and there is no serious organic lesion.

Exclusion criteria

Exclusion criteria: 1. Secondary Parkinson's disease or Parkinson's syndrome; 2. Merge other important organ lesions such as heart, liver, and kidney in the system; 3. Patients with concomitant mental illness or cognitive impairment, 4. Those who are unable to complete the scale or voluntarily withdraw from this study midway.

Design outcomes

Primary

MeasureTime frame
Parkinson's scale;

Secondary

MeasureTime frame
Tau;p-Tau;Aß42;s100ß;IL-17, IL-1ß, TNF-a;MDH, SOD;

Countries

China

Contacts

Public ContactFang Kang

The First Affiliated Hospital of University of Science and Technology

kangfang199771@163.com+86 181 5512 7799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026